Delivery Order SPE2DB22D3016-SPE2DB25FBGT1
- Not listed
- The Defense Logistics Agency awarded a $1,269.13 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $1,138.69 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg, with an ultimate completion date of August 21, 2025. This is a firm fixed price, non-set-aside contract performed at the vendor's Conshohocken, Pennsylvania location. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December...
- The Defense Logistics Agency awarded a $2,735.43 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 10 mg on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is executed as a child order under AmerisourceBergen's larger prime contract vehicle. The pharmaceutical product will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $2,565.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 50 mg on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-set-aside contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The product will be...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a delivery order valued at $2,122.77 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 30 mg, a prescription stimulant medication commonly used to treat attention deficit hyperactivity disorder. The contract was competitively awarded with no set-aside designation and carries a firm fixed price structure, with an ultimate completion date of August 20, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $6,467.94 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100 count) on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitive award, structured as a firm fixed-price delivery order with no set-aside designation, is performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a $1,547.46 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg on August 19, 2025, with an ultimate completion date of August 20, 2025. This non-set-aside, firm fixed price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The order will be fulfilled from the vendor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,832.02 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 60 mg, with a completion date of July 24, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, issued competitively to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract valued at $1,927.86. The order was competitively awarded without set-aside designation and is scheduled for completion by July 31, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location and serve as the prime contractor on this delivery order, which...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBGT1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,679.97 to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 70 mg, with an ultimate completion date of September 2, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical procurement vendor with an extensive portfolio of brand-name and generic medications, vaccines, and specialized healthcare commodities. Through its DLA IDC vehicle, the company supports the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems with medications spanning multiple therapeutic domains. This particular delivery order for Vyvanse—a controlled substance commonly used for attention-deficit/hyperactivity disorder treatment—represents one of numerous small-value transactions the contractor fulfills under its prime vendor arrangement to support military medical supply chain requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/29/25 |